[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-urge-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-urge-incontinence":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,72,91,116,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100528494","phase-2-surface-electrical-stimulation-for-urinary-incontinence-in-men-treated-for-prostate-cancer-100528494",false,"NCT06161506","Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer","A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer","* INCLUSION CRITERIA:\n* Participants must be male.\n* Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.\n* Participants must have at least one of the following types of urinary incontinence:\n\n  * stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing\n  * urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.\n* Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.\n* Participants must be able to read and write in English.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C= 2.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Change of therapy for prostate cancer planned during the study intervention.\n* History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.\n* Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (\\>= 4 UTIs within the 12 months prior to the study treatment initiation).\n* History of complete denervation of the pelvic floor.\n* Severe obesity (body mass index \\[BMI\\] \\>35).\n* Pelvic pain\u002Fpainful bladder syndrome.\n* Metal implant in the abdominal or pelvic area.\n* History of chronic cough with ongoing symptoms\n* An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.\n* History of epilepsy.\n* History of underlying neurologic\u002Fneuromuscular disorder that could contribute to urinary incontinence.\n* Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.\n* Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.","MALE","18 Years","120 Years",{"count":20,"type":21},41,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nMen who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.\n\nObjective:\n\nTo see if the Elidah device can reduce urinary incontinence after prostate treatment.\n\nEligibility:\n\nMen aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.\n\nDesign:\n\nParticipants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.\n\nThe Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.\n\nParticipants will be given an Elidah device and taught how to use it at home.\n\nThey will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.\n\nParticipants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.\n\nParticipants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.\n\nParticipants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.\n\nParticipants will complete 15-minute questionnaires.",[27,28,29],"Urinary Urge Incontinence","Stress Urinary Incontinence","Prostatic Hyperplasia",[31,32,33],"Elidah Device","Urinary Incontinence","Prostate Cancer","RECRUITING","2026-04-14",{"date":37,"type":38},"2026-04-15","ACTUAL",{"date":40,"type":38},"2024-02-15",{"date":42,"type":21},"2028-03-01",{"name":44,"class":45},"National Cancer Institute (NCI)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100622443","freedom-registry---follow-up-revision-experience-and-evaluation-of-device-outcomes-metrics-100622443","NCT07383688","FREEDOM Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics","Follow-up Revision Experience and Evaluation of Device Outcomes Metrics in Subjects Receiving Replacement of Traditional Sacral Neuromodulation (SNM) With the Neuspera SNM System","Inclusion Criteria:\n\n1. Currently have a traditional SNM device and has decided to have the device replaced with the Neuspera SNM System OR previously had an existing traditional SNM implant that was completely removed within the last year\n2. Is 22 years of age or older\n3. Had documented at least 50% improvement in UUI episodes on a bladder diary with either a stimulation trial or with their traditional system\n4. Is a good surgical candidate and qualified to receive the Neuspera SNM System per the device labeling\n5. Is capable of participating in all testing and follow-up clinic visits associated with this clinical study.\n\nExclusion Criteria:\n\n1. Has a contraindication for the Neuspera SNM System per the device labeling.\n2. Has plans to enroll or is currently enrolled in another investigational device or drug trial during his\u002Fher participation in this study","ALL","22 Years",{"count":57,"type":21},100,"OBSERVATIONAL","Single-arm study where subjects' responses to a questionnaire for the traditional Sacral Neuromodulation (SNM) devices will be compared to the responses regarding the Neuspera SNM System.",[27],"NOT_YET_RECRUITING","2026-03-03",{"date":64,"type":38},"2026-03-05",{"date":66,"type":21},"2026-03",{"date":68,"type":21},"2026-10",{"name":70,"class":71},"Neuspera Medical, Inc.","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":46},"100611942","study-of-30-minute-stimulation-with-the-neuspera-sacral-neuromodulation-snm-system-100611942","NCT07247136","Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System","Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)","Inclusion Criteria:\n\n* Is male or female 22 years of age or older.\n* Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening baseline visit date.\n* Has failed, could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects), or not a good candidate for (as determined by treating physician) at least one (1) antimuscarinic or β3 adrenoceptor agonist medication.\n* Is willing and able to washout (at least five half-lives) from OAB medications for a period determined appropriate based on type of OAB medication prior to the baseline bladder diary and remain off OAB medications through the study duration OR must be willing to maintain medication through the study duration.\n* Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary.\n* Has a positive stimulation trial with a 50% reduction in UUI episodes.\n\nExclusion Criteria:\n\n* Has a contraindication for the Neuspera SNM System per the device labeling.\n* Has a hemoglobin A1c of \\>8%.\n* Has glucosuria.\n* Has diabetic neuropathy.\n* Has interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines, chronic pelvic pain, or recurrent symptomatic urinary tract infections.\n* Has skin, orthopedic, neurological, or hematological (bleeding disorder) or anatomical limitations that could prevent successful placement of the neurostimulator.\n* Has broken, blistered skin or compromised circulation in the area of the neurostimulator implant.\n* Has neurogenic bladder dysfunction such as traumatic or atraumatic myelopathy, multiple sclerosis, Parkinsonism, or history of cerebrovascular accident.\n* Has documented urinary retention within 6 months prior to the screening baseline visit date.\n* Has clinically significant bladder outlet obstruction.\n* Is currently undergoing or has previously undergone pelvic irradiation.\n* Is a subject with a mechanical obstruction such as benign prostatic hypertrophy, urethral stricture, or cancer.\n* Has current grade 3 or 4 pelvic organ prolapse including cystocele, rectocele, enterocele, procidentia or vaginal vault prolapse.\n* Has received tibial nerve stimulation (TNS) in the past 3 months for the treatment of overactive bladder or unwilling to stay off TNS therapy for the study duration.\n* Has received treatment of urinary symptoms with any botulinum neurotoxin type-A (BoNT-A) agent in the past 6 months; (e.g. obotulinumtoxinA, Botox,® abobotulinumtoxinA, Dysport® IncobotulinumtoxinA, Xeomin®).\n* Is a woman who is pregnant or planning to become pregnant during this clinical study or is a woman of child-bearing potential who is not using a medically acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with clear negative result.\n* Has previously had SNM therapy.\n* Has active implantable medical devices such as neurostimulators, drug pumps, pacemakers, or internal defibrillators since compatibility has not been assessed.",{"count":80,"type":21},30,[82],"NA","Single-arm study conducted in participants for the treatment of urinary urge incontinence in patients who have failed, could not tolerate, or were not a candidate for more conservative treatments.\n\nThe objective of the study is to assess the effectiveness of 30-minutes daily therapeutic stimulation with the Neuspera System.",[27],{"date":64,"type":38},{"date":87,"type":38},"2025-11-19",{"date":89,"type":21},"2026-11",{"name":70,"class":71},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100491922","a-real-world-study-of-ecoin-for-urgency-urinary-incontinence-post-approval-evaluation-recipe-100491922","NCT05685433","A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)","RECIPE","Inclusion Criteria:\n\n* Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population\n* Individual with diagnosis of overactive bladder with urgency urinary incontinence.\n* Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.\n* Individual gives written informed consent.\n* Individual is mentally competent and able to understand all study requirements.\n* Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.\n* Individual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to baseline or longer if the physician judges that the therapeutic effect is still present.\n* Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).\n* Individual is determined to be a suitable surgical candidate by physician.\n* Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.\n\nExclusion Criteria:\n\n* Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.\n* Individual has clinically significant bladder outlet obstruction. (Suspected bladder outlet obstruction will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has predominantly stress urinary incontinence (greater than 1\u002F3 of leaks on baseline diary are stress).\n* Individual has an active urinary tract infection at time of enrollment.\n* Individual has known polyuria.\n* Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome.\n* Individual has abnormal post void residual (i.e. greater than 200 cc initially and on repeat testing after double voiding)\n* Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.\n* Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.\n* Individual has had diagnosis of bladder, urethral, or prostate cancer.\n* Individual has had a prior anti-stress incontinence sling surgery within the last year.\n* Individual is pregnant or intends to become pregnant during the study.\n* Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.\n* Individual has uncontrolled diabetes mellitus (Hemoglobin A1C\\>7) or diabetes with significant peripheral complications. (Uncontrolled diabetes will be ruled out by blood test excluding those with Hemoglobin A1C\\>7).\n* Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator (ICD).\n* Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment, or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual has been treated with percutaneous tibial nerve stimulation (PTNS) within the previous 4 weeks prior to enrollment or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual is currently using transcutaneous electrical nerve stimulation (TENS) in the pelvic region, back, or legs.\n* Individual is aware that he or she will need an MRI scan other than a head\u002Fneck\u002Fshoulder MRI during the study period.\n* Individual has a clotting or bleeding disorder or is using anticoagulant therapies and in the opinion of the investigator is not a good candidate for the study (antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator).\n* Individual is neutropenic or immune-compromised.\n* Individual has had previous surgery and\u002For significant scarring at the implant location.\n* Individual has ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders.\n* Individual has a clinically significant peripheral neuropathy in the lower extremities.\n* Individual has neurogenic bladder dysfunction.\n* Individual has pitting edema at implant location (≥ 2+ is excluded).\n* Individual has inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.\n* Individual has varicose veins and is symptomatic.\n* Individual has open wounds, trauma, or prior surgery in the lower extremities.\n* Individual has arterial disease in the lower extremities.\n* Individual has vasculitis in the lower extremities.\n* Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBC's \u002FHPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)\n* In the opinion of the investigator, Individual is not a good candidate for participation in the study.",{"count":99,"type":21},200,[82],"A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).",[103,104,105,27],"Overactive Bladder","Urge Incontinence","Incontinence, Urinary","2026-01-26",{"date":108,"type":38},"2026-01-28",{"date":110,"type":38},"2023-01-26",{"date":112,"type":21},"2031-12",{"name":114,"class":71},"Valencia Technologies Corporation",22,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":46},"100607111","platelet-rich-plasma-versus-botulinum-toxin-for-refractory-overactive-bladder-a-randomized-trial-100607111","NCT07184307","Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial","Intra-vesical Injection of Platelet-Rich Plasma Compared With Botox for Management of Patients With Refractory Overactive Bladder: A Comparative Randomized Study","Inclusion Criteria:\n\n* Age 18 years or older\n* History of urgency, frequency, nocturia, with or without urge urinary incontinence, lasting for at least 6 months\n* Failure of standard medical treatment (antimuscarinics, beta-3 adrenergic agonists, or other appropriate therapy) for at least 6 months\n* Willing and able to complete bladder diaries, questionnaires, and urodynamic testing\n* Provides informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Previous intravesical biological therapy (e.g., platelet-rich plasma or botulinum toxin)\n* Prior pelvic or bladder surgery that may affect bladder function\n* Active urinary tract infection or sexually transmitted infection\n* Vaginitis or chronic bacterial prostatitis\n* Bladder or lower ureteral stones confirmed by imaging\n* Bladder outlet obstruction on urodynamic study\n* Bladder malignancy (mass on imaging or malignant cells on cytology)\n* Use of indwelling urinary catheter\n* Severe uncontrolled medical conditions (e.g., uncontrolled diabetes, advanced renal or hepatic impairment)\n* Known hypersensitivity to botulinum toxin or contraindication to platelet-rich plasma preparation (e.g., coagulopathy, inability to discontinue anticoagulation safely)",{"count":124,"type":21},48,[82],"Overactive bladder is a common condition that causes sudden urges to urinate, frequent urination, night-time urination, and sometimes leakage of urine. Many people with overactive bladder improve with lifestyle changes and medicines. However, some patients do not respond to these standard treatments and continue to suffer from bothersome symptoms. This study is designed to help patients who have not improved with available medical therapy.\n\nTwo treatments will be compared in this research. The first treatment uses platelet-rich plasma. Platelet-rich plasma is made from a patient's own blood and contains growth factors that may help repair the lining of the bladder and improve bladder function. The second treatment uses botulinum toxin. Botulinum toxin is a protein that can reduce unwanted bladder contractions and is already approved for use in patients with overactive bladder who did not respond to other treatments.\n\nThe purpose of this study is to evaluate whether platelet-rich plasma injection into the bladder wall is safe, effective, and durable when compared with botulinum toxin injection into the bladder muscle. We believe that platelet-rich plasma may improve bladder health by encouraging tissue repair and reducing inflammation, while botulinum toxin may reduce bladder overactivity by blocking chemical signals that cause muscle contractions.\n\nThis study will take place at Benha University Hospital in Egypt. About 48 adult participants with overactive bladder that has not improved after at least six months of medical therapy will be enrolled. Participants will be randomly assigned to one of two groups. One group will receive platelet-rich plasma injections into the bladder lining, and the other group will receive botulinum toxin injections into the bladder muscle. The procedures will be performed under anesthesia using a cystoscope, which is a thin instrument inserted into the bladder.\n\nParticipants will be followed for one year. At several time points during follow-up, they will complete bladder symptom questionnaires, keep a voiding diary, and undergo urodynamic studies to measure bladder capacity and function. Researchers will also monitor safety by recording any side effects, such as urinary tract infections or temporary difficulty emptying the bladder.\n\nThe main goal of this study is to determine whether platelet-rich plasma can reduce symptoms of overactive bladder as effectively as botulinum toxin, with fewer side effects and longer-lasting results. If successful, platelet-rich plasma could offer a new treatment option for patients who continue to struggle with overactive bladder despite standard medical therapy.",[128,27,129],"Overactive Bladder Syndrome","Detrusor Overactivity",[131,132,103,133,134,135,136,129,137,138],"Platelet-Rich Plasma","Botulinum Toxin Type A","Refractory Overactive Bladder","Urinary Urgency","Urinary Frequency","Urge Urinary Incontinence","Intravesical Injection","Regenerative Therapy","2025-09-13",{"date":141,"type":38},"2025-09-19",{"date":143,"type":38},"2025-04-15",{"date":37,"type":21},{"name":146,"class":147},"Benha University","OTHER",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":155,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100385978","phase-4-post-procedural-pain-associated-with-5-versus-20-intravesical-injections-of-onabotulinumtoxin-a-100385978","NCT04305743","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A for Treatment of Overactive Bladder: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Women \\>=18 years of age with diagnosis of urinary urgency, urinary frequency, urgency urinary incontinence, overactive bladder.\n* Procedure scheduled in either the outpatient clinic or the operating room to be performed without use of sedation, general, or neuraxial anesthesia.\n\nExclusion Criteria:\n\n* Male gender.\n* Women \\\u003C18 years of age.\n* Non-English speaking.\n* Pregnancy (patient will self-report pregnancy).\n* Participant has symptoms of overactive bladder due to any known neurological reason (e.g. spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc.)\n* Participant uses clean intermittent catheterization or indwelling catheter to manage urinary incontinence.\n* Participant has a history or current diagnosis of bladder cancer or other urothelial malignancy.\n* Participant has a known allergy or sensitivity to any botulinum toxin preparation.\n* Participant has any medical condition that may put her at increased risk with exposure to onabotulinumtoxin A, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.\n* Participant is scheduled for administration of onabotulinumtoxin A with use of sedation, general, or neuraxial anesthesia.","FEMALE",{"count":157,"type":21},60,[159],"PHASE4","Currently, in clinical practice there has been no standardization in the number of injections a single dose of intradetrusor onabotulinumtoxin A is administered in. Given the increasing use of this treatment modality, the aim of this study is to compare outcomes for patients given a 100 unit dose of onabotulinumtoxin A split into 5 as compared to 20 injections for the treatment of overactive bladder or urgency urinary incontinence refractory to medical treatment.",[162,163,105,27,164,165],"Urinary Bladder, Overactive","Incontinence, Urge","Urinary Frequency More Than Once at Night","Nocturia",[167,168,169,170,171],"overactive bladder","urgency urinary incontinence","onabotulinumtoxin","bladder","botox","2020-11-03",{"date":174,"type":38},"2020-11-05",{"date":176,"type":38},"2019-10-09",{"date":178,"type":21},"2021-06-01",{"name":180,"class":147},"University of South Florida",2]